News
AMSBIO has published an informative online article that reviews the importance of culture techniques for induced pluripotent stem cells (iPSCs), which provide an invaluable resource for drug discovery and therapeutic applications.
When using iPSCs for drug discovery and therapeutic applications, it is vital to generate a homogenous culture. The absence of uniformity in iPSC culture can severely compromise the quality and quantity of data generated.
Agreement builds on and complements Daiichi Sankyo and MSD’s shared commitment to develop novel medicines for patients with cancer
Daiichi Sankyo and MSD to co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where MSD retains exclusive rights
Sandwich, Kent, UK / 6th August 2024 / Asymchem Laboratories (Tianjin) Co., Ltd. has officially inaugurated its new European development and pilot manufacturing site at Discovery Park in Sandwich, Kent, U.K., marked with a ribbon cutting on Friday 2 August by Dr. Hao Hong, Chairman, Founder, and CEO of Asymchem.
KISS is conducting a 2-minute survey to gather insights on the integration and usage of AI in business and marketing operations across different sectors including, Science, Technology, Education, Agriculture and Professional Services.
We are looking to help identify industry trends, support needs, and guide innovation and anonymised results will be shared with all participants.
Questions we are asking include:
Continuous 2 is an active project aiming to address the growing demand for cost-effective biologics treatments. With the global biopharmaceutical market estimated to grow to 3.9bn by 2024, the industry must act quickly to make these life-changing drugs more accessible to patients, and respond to the demand for flexible manufacturing technology that delivers real-time release of biotherapeutics.
UK Continuous 2 is building on the achievements of two previous projects:
The July edition of our People Pathways newsletter is now available to read here.
You can read about:
✴ New and upcoming One Nucleus courses
✴ Registration open for the next BLSA SIG webinar
✴ Reflections and takeaways from our Neurodiversity webinar
✴ New mentoring opportunities
and more...
French biophysics pioneer Depixus has launched its inaugural Research Program, offering free access to the company’s unique single molecule interactomics technology.
Depixus’ scalable magnetic force spectroscopy (MFS) platform is the first technology that allows researchers to simultaneously explore dynamic interactions between thousands of individual molecules in near real-time.
Boston MA and London UK, 31 July 2024 - One Nucleus and Life Science Nation (LSN) are pleased to announce the co-location of their renowned Genesis 2024 and Redefining Early Stage Investments (RESI) conferences, scheduled to take place on 4 December 2024, in London. The Genesis Conference programme will be at 1 Wimpole Street, and RESI will be at 11 Cavendish Square, allowing attendees to participate in either or both events just a few steps away from each other.
Metrion Biosciences' webinar ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ enabled attendees to learn how an hiPSC-CM model can help provide clear decision-making data for their project team, avoiding costly issues related to QTc and QRS cardiac liabilities in the clinic.
Presentations were received from: